Farther Finance Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $394K | Buy |
8,093
+2,467
| +44% | +$120K | 0.01% | 1025 |
|
|
2025
Q1 | $186K | Buy |
5,626
+1,792
| +47% | +$59.4K | ﹤0.01% | 1256 |
|
|
2024
Q4 | $151K | Buy |
3,834
+977
| +34% | +$38.5K | 0.01% | 1123 |
|
|
2024
Q3 | $134K | Buy |
2,857
+195
| +7% | +$9.16K | 0.01% | 1173 |
|
|
2024
Q2 | $144K | Buy |
2,662
+68
| +3% | +$3.67K | 0.01% | 983 |
|
|
2024
Q1 | $177K | Buy |
2,594
+502
| +24% | +$34.2K | 0.01% | 728 |
|
|
2023
Q4 | $131K | Buy |
2,092
+1,892
| +946% | +$118K | 0.01% | 702 |
|
|
2023
Q3 | $9.08K | Sell |
200
-160
| -44% | -$7.26K | ﹤0.01% | 1318 |
|
|
2023
Q2 | $20.2K | Sell |
360
-379
| -51% | -$21.3K | ﹤0.01% | 993 |
|
|
2023
Q1 | $33.4K | Buy |
739
+728
| +6,618% | +$32.9K | 0.01% | 732 |
|
|
2022
Q4 | $447 | Buy |
+11
| New | +$447 | ﹤0.01% | 1854 |
|